California State Teachers Retirement System grew its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 13,901.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,562,256 shares of the medical instruments supplier's stock after acquiring an additional 14,458,254 shares during the quarter. California State Teachers Retirement System owned 21.00% of Insulet worth $2,217,103,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently made changes to their positions in PODD. BlackRock Inc. bought a new position in Insulet in the 2nd quarter valued at approximately $1,018,582,000. Norges Bank bought a new position in shares of Insulet in the 4th quarter valued at $300,794,000. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Insulet by 462.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier's stock valued at $258,088,000 after acquiring an additional 1,011,369 shares in the last quarter. Man Group plc bought a new stake in Insulet during the 2nd quarter worth $78,746,000. Finally, Bank of America Corp DE bought a new stake in Insulet during the 2nd quarter worth $64,921,000.
Insulet Stock Down 2.0%
Shares of NASDAQ:PODD opened at $131.96 on Friday. The business's 50 day simple moving average is $152.36 and its two-hundred day simple moving average is $173.92. The firm has a market cap of $9.15 billion, a P/E ratio of 24.67, a PEG ratio of 1.06 and a beta of 1.08. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. Insulet Corporation has a 52-week low of $126.40 and a 52-week high of $354.88.
Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. During the same quarter in the previous year, the company posted $1.17 earnings per share. The company's quarterly revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, research analysts forecast that Insulet Corporation will post 6.51 EPS for the current fiscal year.
Wall Street Analyst Weigh In
PODD has been the topic of a number of recent research reports. BTIG Research lowered Insulet from a "buy" rating to a "neutral" rating in a research note on Thursday, August 6th. Leerink Partners lowered shares of Insulet from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $247.00 to $145.00 in a report on Thursday, August 6th. Royal Bank Of Canada cut their target price on shares of Insulet from $245.00 to $160.00 and set an "outperform" rating on the stock in a research report on Thursday, August 6th. Robert W. Baird set a $175.00 price objective on Insulet in a report on Thursday, August 6th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on Insulet in a research report on Tuesday, June 23rd. They set a "buy" rating and a $190.00 target price for the company. Fourteen research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $195.40.
Get Our Latest Report on Insulet
Insulet Company Profile
(
Free Report)
Insulet Corporation is a medical device company that develops, manufactures and sells wearable insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.
The company's principal product platform is Omnipod, a tubeless, wearable insulin pump system. Omnipod products include the disposable, wearable Pod and related management and smartphone-based technologies.
Further Reading
Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
